**Supplemental Analyses and Results**

**Missing Subject Analysis**

A portion of the current sample is missing data for the emotion recognition memory task (*n* = 1070; i.e., 22.38% of the current sample). This rate of data loss is likely due to the timing of the emotion recognition memory task. The emotion recognition memory task is administered after a 90-minute neuroimaging protocol and therefore is not administered to participants who either refused to complete the entire neuroimaging protocol, or who refused to continue the session after the prolonged neuroimaging sequence due to discomfort or fatigue. We ran a binary logistic regression model with task completion as the outcome variable and CD symptomatology, sex, race, age, and data collection site as simultaneous predictors to examine if task completion varied by these predictors.

Rates of CD symptomatology, our primary predictor of interest, did not meaningfully differ among those who completed and those who did not, β = -.056, 95% CI [-.1248 .0125]. However, there were effects for the covariates of non-interest (e.g., demographic factors): sex, β = .216, 95% CI [.0810 .3536], where female participants were more likely to have emotion recognition task data than male participants; age, β = .139, 95% CI [.0687 .2108], where older participants were more likely to have emotion recognition task data than younger participants; and, race, β = .224, 95% CI [.0755 .3791], where non-white participants were more likely to have emotion recognition task data than white participants. Additionally, there was one data collection site with a higher rate of available emotion recognition task data, β = 1.144, 95% CI [.0832 1.971], however no other sites meaningfully differed in their rates of available emotion recognition task data (βs ranged from -.769 to .911).

**NIH Toolbox Task Scores**

 While our *a priori* global hypotheses focus on examining domain-general neurocognitive functioning (as measured by the NIH Toolbox cognition battery total cognition corrected T-score), it is possible that CD symptomatology is related to more specific aspects of neurocognitive functioning. For the sake of completeness, we ran zero-order correlation and partial correlation analyses examining the relationships among CD symptomatology and the individual NIH Toolbox cognition battery task and composite scores (see Table S1 for descriptive statistics and Tables S2 and S3 for the correlation findings).

**Cortical Network Nodes**

While our *a priori* node-level analyses focused on examining the relationships between CD symptomatology and subcortical structures, we also completed exploratory analyses examining the impact of CD symptomatology on node-level metrics for each cortical network. These exploratory analyses used the same regression models described for the main node-level analysis (see *Methods: Data Analysis: Node-Level Analysis*). Results from these analyses revealed that CD symptomatology was not meaningfully related to any node-level metrics for cortical network nodes. The complete list of CD-related effects from this exploratory analysis can be found in Table S4.

**CD Diagnosis**

 To investigate whether our CD symptomatology-related effects replicated at a diagnostic group-level, we sorted participants into two groups: youth who met *DSM-5* diagnostic criteria for CD based on the Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (K-SADS-PL; Kaufman et al., 2013)(CD group; *n* = 219) and youth who did not endorse symptoms of psychopathology (“healthy controls” [HC] group; specific criteria for participants classified as HC were taken from Waller et al., [2020]; *n* = 288). Youth who did not meet criteria for either the CD or HC groups were excluded from these analyses. Then we reran all regression analyses (see *Methods: Data Analysis*) using a group-level CD variable (dichotomously coded, CD vs. HC) as our primary predictor of interest.

 **Global Analysis.**

 ***Global Graph Analysis*.** The group-level analysis replicated our main global analysis finding that CD is associated with higher global clustering coefficients, *F*(5, 501) = 3.738, *p* = .002, β = .117, 98.75% CI [.0020 .2346]. Similarly, as in our main analysis, CD was not related to any other global differences after correcting for multiple comparisons (Degreemax, *F*(5, 501) = 2.530, *p* = .028, β = .087, 98.75% CI [-.0348 .2029]; *BC*max, *F*(5, 501) = 4.085, *p* = .001, β = .098, 98.75% CI [-.0180 .2156]; efficiencyglobal, *F*(5, 501) = 1.868, *p* = .098, β = -.051, 98.75% CI [-.1685 .0668]).

 ***Neurocognitive Functioning.*** Similar to our main analysis, this grouped analysis replicated that CD was associated with generally lower neurocognitive functioning as measured by the NIH Toolboxcognition battery corrected cognition total composite T-score, *F*(5, 454) = 9.783, *p* < .001, β = -.300, 95% CI [-.3928 -.2070].

 **Node-Level Analysis.**

***Node-Level Metrics: Subcortical.*** The group-level analysis replicated that CD was associated with lower Degreesubcortical, but only prior to correction, *F*(5, 501) = 7.218, *p* < .001, β = -.091, 95% CI [-.1830 -.0048], 98.33% CI [-.2024 .0156]. This failure to detect a corrected CD effect may be due to the substantial drop in power from the full sample (*n* = 4781) to the subsample (*n* = 507) used in the grouped analysis. Additionally, CD was not associated with *BC*subcortical, *F*(5, 501) = 2.526, *p* = .028, β = .072, 98.33% CI [-.0367 .1873], or local efficiencysubcortical, *F*(5, 501) = 3.671, *p* = .003, β = .087, 98.33% CI [-.0109 .2035], in the grouped analysis.

***Emotion Recognition Memory.*** This grouped analysis replicated the main effect of CD on task performance where youth with CD displayed worse performance on the emotion recognition memory task across all three face stimuli, *F*(1, 362) = 8.525, *p* = .004, β = -.233, 95% CI [-.3356 -.1313]. Also, consistent with our main analysis, there was not a CD X Facial expression interaction, *F*(2, 724) = 0.135, *p* = .874.

**Demographic Interactions with CD Symptomatology**

Prior research has demonstrated that the neurocognitive underpinnings of CD may differ by sex (Decety, Yoder, & Lahey, 2015; Smaragdi et al., 2017) and race (Wiesner et al., 2015). All analyses (see *Methods: Data Analysis*) were rerun with a CD symptomatology X Sex interaction variable or a CD symptomatology X Race interaction variable included in the model.

 **CD Symptomatology X Sex Interactions.**

 ***Global Analysis.***

*Global Graph Analysis.* There were no CD symptomatology X Sex interactions for any of the global graph theory metrics after controlling for multiple comparisons (βs ranged from -.061 through -.005).

 *Neurocognitive Functioning.* There was a CD symptomatology X Sex interaction for the impact of CD symptomatology on neurocognitive functioning as measured by the NIH Toolbox cognition battery, *F*(6, 4368) = 15.063, *p* < .001, β = .074, 95% CI [.0234 .1253]. Unpacking this interaction, higher levels of CD symptomatology were associated with lower performance on the NIH Toolbox cognition battery for both male, β = -.127, 95% CI [-.1666 -.0893], and female participants, β = -.089, 95% CI [-.1281 -.0497], however the effect was stronger in male participants.

 ***Node-Level Analysis.***

 *Node-Level Analysis: Subcortical.* There were no CD symptomatology X Sex interactions for any of the node-level graph theory metrics after controlling for multiple comparisons (βs ranged from -.054 through .044).

 *Emotion Recognition Memory.* Neither the CD symptomatology X Sex interaction, *F*(1, 3687) = 0.792, *p* = .374, nor the CD symptomatology X Sex X Facial expression interaction, *F*(2, 7374) = 2.013, *p* = .134, were meaningful.

**CD Symptomatology X Race Interactions.**

 ***Global Analysis.***

*Global Graph Analysis.* There were no CD symptomatology X Race interactions for any of the global graph theory metrics (βs ranged from -.035 through .008).

 *Neurocognitive Functioning*. Race did not moderate the effect of CD symptomatology on neurocognitive functioning as measured by the NIH Toolbox cognition battery (CD symptomatology X Race interaction: β = -.037, 95% CI [-.0823 .0073]).

 ***Node-Level Analysis.***

 *Node-Level Analysis: Subcortical.* There was a CD symptomatology X Race interaction on local efficiencysubcortical, *F*(6, 4774) = 5.237, *p* < .001, β = .065, 98.33% CI [.0077 .1350]. Unpacking this interaction, white participants do not show an association between CD symptomatology and local efficiencysubcortical, β = -.009, 95% CI [-.0291 .0144]. In contrast, higher CD symptomatology was related to higher local efficiencysubcortical in non-white participants, β = .068, 95% CI [.0163 .1336], suggesting that there may be a relationship between CD symptomatology and heightened local efficiencysubcortical unique to non-white youth, possibly reflecting differences in structural societal factors that often differentiate white and non-white youth in the United States and that can impact brain functioning and structure (Freedman & Woods, 2013; Kim, Evans, Chen, Miller, & Seeman, 2018). Race did not moderate the effect of CD symptomatology on either Degreesubcortical, *F*(6, 4774) = 24.439, *p* < .001, β = -.037, 98.33% CI [-.0974 .0178], or *BC*subcortical, *F*(6, 4774) = 2.551, *p* = .018, β = .023, 98.33% CI [-.0455 .0958].

*Emotion Recognition Memory.* Neither the CD symptomatology X Race interaction, *F*(1, 3687) = 0.981, *p* = .322, nor the CD symptomatology X Race X Facial expression interaction, *F*(2, 7374) = 0.015, *p* = .985, were meaningful.

**Uniqueness to CD**

While the current findings demonstrate that CD is related to various neural and neurocognitive abnormalities, it is possible that these neurocognitive differences are not unique to CD but rather shared across multiple externalizing psychopathologies. To assess whether these effects also are present in other externalizing psychopathologies, we reran all of our regression analyses (see *Methods: Data Analysis*) two times, once with oppositional defiance disorder (ODD) symptomatology (as measured by the K-SADS-PL)[[1]](#footnote-2) as the primary predictor of interest, and once with attention deficit hyperactivity disorder (ADHD) symptomatology (as measured by the K-SADS-PL)[[2]](#footnote-3) as the primary predictor of interest. In both cases, CD symptomatology was removed as a factor from the models.

 **ODD Effects**

 ***Global Analysis.***

*Global Graph Analysis.* Unlike CD, ODD symptomatology was not related to global clustering, *F*(5, 4394) = 9.931, *p* < .001, β = .011, 98.75% CI [-.0251 .0491]. Additionally,ODD symptomatology was not related to global Degreemax, *F*(5, 4394) = 6.962, *p* < .001, β = .029, 98.75% CI [-.0115 .0698], global *BC*max, *F*(5, 4394) = 9.105, *p* < .001, β = .011, 98.75% CI [-0.0262 0.0490], or global efficiency, *F*(5, 4394) = 4.430, *p* = .001, β = .005, 98.75% CI [-.0324 .0436].

 *Neurocognitive Functioning*. Similar to CD, higher ODD symptomatology was related to generally impaired neurocognitive functioning as measured by the NIH Toolboxcognition battery corrected cognition total composite T-score, *F*(5, 4007) = 8.199, *p* < .001, β = -.052, 95% CI [-.0846 -.0205].

 ***Node-Level Analysis.***

*Node-Level Metrics: Subcortical*. In contrast with CD, ODD symptomatology was not related to Degreesubcortical, *F*(5, 4394) = 22.192, *p* < .001, β = -.025, 98.33% CI [-.0623 .0120]. Similarly, ODD symptomatology was not related to *BC*subcortical, *F*(5, 4394) = 1.701, *p* = .131, β = .019, 98.33% CI [-.0211 .0660], or subcortical efficiency, *F*(5, 4394) = 3.186, *p* = .007, β = .001, 98.33% CI [-.0336 .0417].

*Emotion Recognition Memory.* Similar to CD, there was a main effect of ODD symptomatology on task performance where youth higher on ODD symptomatology generally performed worse on the emotion recognition memory task across all three face stimuli conditions, *F*(1, 3405) = 5.467, *p* = .019, β = -.040 95% CI [-.0733 -.0068]. Also, consistent with the CD findings, there was not a meaningful ODD X Facial expression interaction, *F*(2, 6810) = 0.329, *p* = .720.

**ADHD Effects.**

***Global Analysis.***

*Global Graph Analysis.* In contrast to CD, ADHD symptomatology was not related to global clustering coefficient, *F*(5, 4321) = 11.137, *p* < .001, β = .016, 98.75% CI [-.0244 .0565]. However, higher ADHD symptomatology was related to higher global Degreemax, *F*(5, 4321) = 8.865, *p* < .001, β = .044, 98.75% CI [.0014 .0843] and higher global *BC*max, *F*(5, 4321) = 11.104, *p* < .001, β = .039, 98.75% CI [.0011 .0776], indicating that, unlike youth higher on CD and/or ODD symptomatology, youth higher on ADHD symptomatology exhibit larger, largest hubs in terms of both hub size (i.e., number of direct connections to the largest hub) and hub centrality in the global flow of information throughout the brain. ADHD symptomatology was not related to global efficiency, *F*(5, 4321) = 5.379, *p* < .001, β = .003, 98.75% CI [-.0365 .0440].

 *Neurocognitive Functioning*. Similar to CD and ODD, higher ADHD symptomatology was related to a general impairment in neurocognitive functioning as measured by the NIH Toolboxcognition battery corrected cognition total composite T-score, *F*(5, 3938) = 17.213, *p* < .001, β = -.114, 95% CI [-.1450 -.0829].

 ***Node-Level Analysis.***

*Node-Level Metrics: Subcortical*. In contrast with CD, ADHD symptomatology did not relate to Degreesubcortical, *F*(5, 4321) = 25.171, *p* < .001, β = -.035, 98.33% CI [-.0732 .0025]. Additionally, ADHD symptomatology was not related to *BC*subcortical, *F*(5, 4321) = 1.629, *p* = .149, β = .004, 98.33% CI [-.0311 .0459], or local efficiencysubcortical, *F*(5, 4321) = 3.275, *p* = .006, β = .014, 98.33% CI [-.0241 .0618].

*Emotion Recognition Memory.* Similar to CD and ODD, there was a main effect of ADHD symptomatology on emotion recognition memory task performance where youth higher on ADHD symptomatology displayed worse performance on the emotion recognition memory task across all three face stimuli conditions, *F*(1, 3355) = 11.174, *p* = .001, β = -.064, 95% CI [-.0954 -.0329]. Also, consistent with the CD and ODD findings, there was not a meaningful ADHD X Facial expression interaction, *F*(2, 6710) = 0.415, *p* = .660.

**Comorbidities.**

Given the high comorbidities across externalizing disorders such as CD, ODD, and ADHD, and the correlations among these phenotypes (correlation between CD symptomatology and ODD symptomatology in the current sample is *r* = .421, 95% CI [.3775 .4614]; correlation between CD symptomatology and ADHD symptomatology in the current sample is *r* = .363, 95% CI [.3196 .4040]), it is possible that either ODD or ADHD symptomatology may be confounding our CD-related findings. To help ensure our main findings are not being confounded by comorbid externalizing psychopathologies, we ran linear regression models examining our main findings (i.e., the main effect of CD symptomatology on: global clustering, NIH Toolbox cognition battery total cognition score, Degreesubcortical, and emotional recognition memory task performance) including CD, ODD, and ADHD symptomatology as simultaneous regressors. The same covariates of non-interest from the main analyses (see *Methods: Data Analysis*)also were included in these models.

**Global Analysis.**

 ***Global Graph Analysis*.** The effect of CD symptomatology on global clustering coefficient remained present, *F*(7, 4188) = 7.997, *p* < .001, β = .045, 95% CI [.0117 .0808], even when controlling for ODD and ADHD symptomatology. In contrast, neither ODD, β = -.007, 95% CI [-.0437 .0290], nor ADHD symptomatology related to global clustering, β = .001, 95% CI [-.0351 .0378].

 ***Neurocognitive Functioning***. The association between higher CD symptomatology and impaired neurocognitive functioning did not meaningfully change when ODD and ADHD symptomatology were included in the model, *F*(7, 3811) = 14.584, *p* < .001, β = -.089, 95% CI [-.1214 -.0568]. Additionally, higher ADHD symptomatology remained related to general neurocognitive impairment, even when controlling for CD and ODD, β = -.097, 95% CI [-.1340 -.0590]; however, ODD symptomatology did not meaningfully relate to neurocognitive impairment when controlling for other externalizing psychopathologies, β = .033, 95% CI [-.0043 .0722].

**Node-Level Analysis.**

***Node-Level Metrics: Subcortical.*** Including ODD and ADHD symptomatology in the model did not meaningfully change the relationship between CD symptomatology and Degreesubcortical, *F*(7, 4188) = 17.148*, p* < .001,β = -.042, 95% CI [-.0794 -.0077]. In contrast, neither ODD, β = .011, 95% CI [-.0252 .0468], nor ADHD symptomatology related to Degreesubcortical, β = -.023, 95% CI [-.0585 .0125].

***Emotion Recognition Memory.*** The relationship between CD symptomatology and impaired emotion recognition memory task performance did not meaningfully change when ODD and ADHD were included in the model, *F*(7, 3271) = 12.044, *p* < .001, β = -.042, 95% CI [-.0797 -.0030]. Similarly, higher ADHD symptomatology still related to worse emotion recognition memory task performance, β = -.049, 95% CI [-.0877 -.0118], even when controlling for CD and ODD. However, the unique variance of ODD symptomatology did not appear to relate to emotion recognition memory task performance, β = -.002, 95% CI [-.0425 .0385].

**Socioeconomic Status**

Prior research indicates that CD may be related to socioeconomic status (SES; Loeber, Green, Keenan, & Lahey, 1995). Moreover, given the modest correlation between CD symptomatology and SES (as measured by self-reported minimum household income divided by number of household members; McLoyd, 1998)[[3]](#footnote-4) in the current sample (*r* = -.129, 95% CI [-.1532 -.1029]), it is possible that SES may be confounding our CD-related findings. To help ensure our main findings are not being confounded by SES, we ran linear regression models examining our four main findings (i.e., the main effect of CD symptomatology on: global clustering, NIH Toolbox cognition battery total cognition score, subcortical degree, and emotional recognition memory task performance) including CD symptomatology as our regressor of interest, the covariates of non-interest used in the main analyses (see *Methods: Data Analysis*), and SES as an additional covariate of non-interest.

**Global Analysis.**

 ***Global Graph Analysis*.** The effect of CD symptomatology on global clustering coefficient remained present when controlling for SES, *F*(6, 4278) = 10.228, *p* < .001, β = .032, 95% CI [.0016 .0641].

***Neurocognitive Functioning***. CD symptomatology remained linked with general neurocognitive impairments even when controlling for SES, *F*(6, 3915) = 23.138, *p* < .001, β = -.087, 95% CI [-.1164 -.0572].

**Node-Level Analysis.**

***Node-Level Metrics: Subcortical.*** Controlling for SES did not meaningfully impact the link between CD symptomatology and decreased Degreesubcortical, *F*(6, 4278) = 21.087, *p* < .001, β = -.046, 95% CI [-.0818 -.0132].

***Emotion Recognition Memory.*** Including SES in the model did not meaningfully change the relationship between CD and reduced performance on the emotion recognition memory task, *F*(6, 3350) = 21.087, *p* < .001, β = -.044, 95% CI [-.0752 -.0118].

**Supplemental References**

Decety, J., Yoder, K. J., & Lahey, B. B. (2015). Sex differences in abnormal white matter development associated with conduct disorder in children. *Psychiatry Research: Neuroimaging, 233*(2), 269-277. https://doi.org/10.1016/j.pscychresns.2015.07.009

Freedman, D., & Woods, G. W. (2013). Neighborhood effects, mental illness and criminal behavior: A review. *Journal of Politics and Law, 6*(3), 1-16. https://doi.org/10.5539/jpl.v6n3p1

Kaufman, J., Birmaher, B., Axelson, D., Perepletchikova, F., Brent, D., & Ryan, N. (2013). Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version 2013 (KSADS-PL).

Kim, P., Evans, G. W., Chen, E., Miller, G., & Seeman, T. (2018). How socioeconomic disadvantages get under the skin and into the brain to influence health development across the lifespan. *Handbook of life course health development* (pp. 463-497): Springer, Cham. https://doi.org/10.1007/978-3-319-47143-3\_19

Loeber, R., Green, S. M., Keenan, K., & Lahey, B. B. (1995). Which boys will fare worse? Early predictors of the onset of conduct disorder in a six-year longitudinal study. *Journal of the American Academy of Child & Adolescent Psychiatry, 34*(4), 499-509.

McLoyd, V. C. (1998). Socioeconomic disadvantage and child development. *American psychologist, 53*(2), 185. https://doi.org/10.1037/0003-066X.53.2.185

Smaragdi, A., Cornwell, H., Toschi, N., Riccelli, R., Gonzalez-Madruga, K., Wells, A., . . . Martin-Key, N. (2017). Sex differences in the relationship between conduct disorder and cortical structure in adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry, 56*(8), 703-712. https://doi.org/10.1016/j.jaac.2017.05.015

Waller, R., Hawes, S. W., Byrd, A. L., Dick, A. S., Sutherland, M. T., Riedel, M. C., . . . Gonzalez, R. (2020). Disruptive behavior problems, callous-unemotional traits, and regional gray matter volume in the ABCD study. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *5*(5), 470-472. https://doi.org/10.1016/j.bpsc.2020.01.002

Wiesner, M., Elliott, M. N., McLaughlin, K. A., Banspach, S. W., Tortolero, S., & Schuster, M. A. (2015). Common versus specific correlates of fifth-grade conduct disorder and oppositional defiant disorder symptoms: Comparison of three racial/ethnic groups. *Journal of Abnormal Child Psychology, 43*(5), 985-998. https://doi.org/10.1007/s10802-014-9955-9

**Supplementary Tables**

*Table S1. Descriptive Statistics for the NIH Toolbox Cognition Battery*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Whole Sample (*N* = 4781) |  | HC (*N* = 288) |  | CD (*N* = 219) |
| Variable | *n* | Min | Max | Mean | Std. Dev |  | *n* | Min | Max | Mean | Std. Dev |  | *n* | Min | Max | Mean | Std. Dev |
| Picture Vocab. | 4481 | 16 | 131 | 52.54 | 10.97 |  | 262 | 26 | 101 | 53.97 | 10.81 |  | 208 | 20 | 81 | 49.76 | 9.81 |
| Flanker | 4480 | 10 | 101 | 46.42 | 9.21 |  | 262 | 17 | 82 | 47.39 | 9.06 |  | 209 | 16 | 81 | 45.35 | 9.58 |
| List Sorting | 4473 | 14 | 90 | 49.52 | 9.76 |  | 262 | 29 | 78 | 51.64 | 9.41 |  | 208 | 18 | 73 | 47.42 | 9.45 |
| Card Sorting | 4483 | 26 | 100 | 47.49 | 9.65 |  | 262 | 29 | 86 | 49.03 | 10.25 |  | 209 | 28 | 86 | 45.97 | 9.63 |
| Pattern Comp. | 4476 | -5 | 100 | 45.16 | 14.46 |  | 262 | -1 | 100 | 47.27 | 15.40 |  | 209 | 10 | 81 | 42.00 | 13.41 |
| Picture Sequence | 4481 | 15 | 96 | 49.47 | 10.87 |  | 262 | 28 | 86 | 51.07 | 10.77 |  | 209 | 22 | 81 | 46.95 | 9.04 |
| Oral Reading | 4479 | 27 | 122 | 49.48 | 11.48 |  | 262 | 33 | 95 | 51.04 | 10.90 |  | 209 | 30 | 109 | 47.13 | 11.67 |
| Fluid Cog. | 4378 | 12 | 105 | 45.89 | 11.10 |  | 252 | 19 | 92 | 48.78 | 11.09 |  | 208 | 14 | 75 | 42.68 | 10.14 |
| Crystallized Cog. | 4391 | 20 | 120 | 51.12 | 11.20 |  | 252 | 31 | 102 | 52.97 | 10.76 |  | 209 | 27 | 99 | 48.18 | 11.08 |
| Total Cog. | 4375 | 13 | 126 | 47.91 | 11.13 |  | 252 | 29 | 88 | 50.83 | 10.72 |  | 208 | 20 | 79 | 44.08 | 10.71 |

HC = Participants classified as “healthy controls” by the criteria put forth in Waller et al., (2020); CD = Participants who met diagnostic criteria for conduct disorder as assessed by the Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (Kaufman et al., 2013); NIH Toolbox = National Institutes of Health (NIH) Toolbox cognition battery; Picture Vocab = NIH Toolbox Picture Vocabulary Test, Fully-Corrected T-score; Flanker = NIH Toolbox Flanker Inhibitory Control and Attention Test, Fully-Corrected T-score; List Sorting = NIH Toolbox List Sorting Working Memory Test, Fully-Corrected T-score; Card Sorting = NIH Toolbox Dimensional Change Card Sort Test, Fully-Corrected T-score; Pattern Comp = NIH Toolbox Pattern Comparison Processing Speed Test, Fully-Corrected T-score; Picture Sequence = NIH Toolbox Picture Sequence Memory Test, Fully-Corrected T-score; Oral Reading = NIH Toolbox Oral Reading Recognition Test, Fully-Corrected T-score; Fluid Cog = NIH Toolbox Fluid Cognition Composite, Fully-Corrected T-score; Crystallized Cog = NIH Toolbox Crystallized Cognition Composite, Fully-Corrected T-score; Total Cog = NIH Toolbox Total Cognition Composite, Fully-Corrected T-score.

*Table S2. Zero-Order Correlations for NIH Toolbox Cognition Battery Scores*

|  |  |
| --- | --- |
|  | Zero-Order Correlations |
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Clinical Variable |  |  |  |  |  |  |  |  |  |  |  |
| 1. CD Symptoms
 | ― | -.07\* | -.03 | -.08\* | -.06\* | -.06\* | -.06\* | -.08\* | -.10\* | -.08\* | -.11\* |
| NIH Toolbox |  |  |  |  |  |  |  |  |  |  |  |
| 1. Picture Vocab.
 |  | ― | .18\* | .25\* | .15\* | .09\* | .15\* | .43\* | .25\* | .83\* | .67\* |
| 1. Flanker
 |  |  | ― | .18\* | .37\* | .32\* | .17\* | .18\* | .62\* | .21\* | .51\* |
| 1. List Sorting
 |  |  |  | ― | .22\* | .14\* | .28\* | .30\* | .55\* | .32\* | .53\* |
| 1. Card Sorting
 |  |  |  |  | ― | .39\* | .19\* | .17\* | .68\* | .19\* | .53\* |
| 1. Pattern Comp
 |  |  |  |  |  | ― | .15\* | .12\* | .71\* | .12\* | .51\* |
| 1. Picture Sequence
 |  |  |  |  |  |  | ― | .17\* | .56\* | .19\* | .46\* |
| 1. Oral Reading
 |  |  |  |  |  |  |  | ― | .29\* | .85\* | .70\* |
| 1. Fluid Cog.
 |  |  |  |  |  |  |  |  | ― | .32\* | .81\* |
| 1. Crystallized Cog.
 |  |  |  |  |  |  |  |  |  | ― | .81\* |
| 1. Total Cog.
 |  |  |  |  |  |  |  |  |  |  | ― |

Correlation analyses were limited to participants with complete NIH Toolbox data (*n* = 4368). Bootstrapped CIs (5000 samples) were used to assess the meaningfulness of the correlations. To correct for multiple comparisons, 99.5% CIs were evaluated to match Bonferroni corrected p-values (1-[.05/10] = .995). CD Symptoms = Number of conduct disorder symptoms present as assessed by the Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (Kaufman et al., 2013); NIH Toolbox = National Institutes of Health (NIH) Toolbox cognition battery; Picture Vocab = NIH Toolbox Picture Vocabulary Test, Fully-Corrected T-score; Flanker = NIH Toolbox Flanker Inhibitory Control and Attention Test, Fully-Corrected T-score; List Sorting = NIH Toolbox List Sorting Working Memory Test, Fully-Corrected T-score; Card Sorting = NIH Toolbox Dimensional Change Card Sort Test, Fully-Corrected T-score; Pattern Comp = NIH Toolbox Pattern Comparison Processing Speed Test, Fully-Corrected T-score; Picture Sequence = NIH Toolbox Picture Sequence Memory Test, Fully-Corrected T-score; Oral Reading = NIH Toolbox Oral Reading Recognition Test, Fully-Corrected T-score; Fluid Cog = NIH Toolbox Fluid Cognition Composite, Fully-Corrected T-score; Crystallized Cog = NIH Toolbox Crystallized Cognition Composite, Fully-Corrected T-score; Total Cog = NIH Toolbox Total Cognition Composite, Fully-Corrected T-score.

\* 99.5% Bootstrapped CI (5000 samples) does not contain 0.

*Table S3. Partial Correlations for NIH Toolbox Cognition Battery Scores*

|  |  |
| --- | --- |
|  | Partial Correlations |
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| Clinical Variable |  |  |  |  |  |  |  |  |  |  |  |
| 1. CD Symptoms
 | ― | -.06\*\* | -.03\* | -.08\*\* | -.06\*\* | -.06\*\* | -.06\*\* | -.07\*\* | -.09\*\* | -.07\*\* | -.10\*\* |
| NIH Toolbox |  |  |  |  |  |  |  |  |  |  |  |
| 1. Picture Vocab.
 |  | ― | .18\*\* | .26\*\* | .14\*\* | .09\*\* | .15\*\* | .42\*\* | .25\*\* | .83\*\* | .67\*\* |
| 1. Flanker
 |  |  | ― | .18\*\* | .37\*\* | .32\*\* | .17\*\* | .18\*\* | .62\*\* | .21\*\* | .51\*\* |
| 1. List Sorting
 |  |  |  | ― | .22\*\* | .15\*\* | .28\*\* | .30\*\* | .55\*\* | .33\*\* | .54\*\* |
| 1. Card Sorting
 |  |  |  |  | ― | .39\*\* | .19\*\* | .17\*\* | .68\*\* | .18\*\* | .53\*\* |
| 1. Pattern Comp
 |  |  |  |  |  | ― | .15\*\* | .12\*\* | .71\*\* | .12\*\* | .51\*\* |
| 1. Picture Sequence
 |  |  |  |  |  |  | ― | .17\*\* | .56\*\* | .19\*\* | .46\*\* |
| 1. Oral Reading
 |  |  |  |  |  |  |  | ― | .29\*\* | .85\*\* | .70\*\* |
| 1. Fluid Cog.
 |  |  |  |  |  |  |  |  | ― | .32\*\* | .81\*\* |
| 1. Crystallized Cog.
 |  |  |  |  |  |  |  |  |  | ― | .81\*\* |
| 1. Total Cog.
 |  |  |  |  |  |  |  |  |  |  | ― |

Correlation analyses were limited to participants with complete NIH Toolbox data (*n* = 4368). Partial correlations controlled for race (dichotomously coded, white vs. non-white), sex (dichotomously coded, female vs. male), age, and site effects. Bootstrapped CIs (5000 samples) were used to assess the meaningfulness of the correlations. To correct for multiple comparisons, 99.5% CIs were evaluated to match Bonferroni corrected p-values (1-[.05/10] = .995). CD Symptoms = number of conduct disorder symptoms present as assessed by the Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (Kaufman et al., 2013); NIH Toolbox = National Institutes of Health (NIH) Toolbox cognition battery; Picture Vocab = NIH Toolbox Picture Vocabulary Test, Fully-Corrected T-score; Flanker = NIH Toolbox Flanker Inhibitory Control and Attention Test, Fully-Corrected T-score; List Sorting = NIH Toolbox List Sorting Working Memory Test, Fully-Corrected T-score; Card Sorting = NIH Toolbox Dimensional Change Card Sort Test, Fully-Corrected T-score; Pattern Comp = NIH Toolbox Pattern Comparison Processing Speed Test, Fully-Corrected T-score; Picture Sequence = NIH Toolbox Picture Sequence Memory Test, Fully-Corrected T-score; Oral Reading = NIH Toolbox Oral Reading Recognition Test, Fully-Corrected T-score; Fluid Cog = NIH Toolbox Fluid Cognition Composite, Fully-Corrected T-score; Crystallized Cog = NIH Toolbox Crystallized Cognition Composite, Fully-Corrected T-score; Total Cog = NIH Toolbox Total Cognition Composite, Fully-Corrected T-score.

\* 95% Bootstrapped CI (5000 samples) does not contain 0.

\*\* 99.5% Bootstrapped CI (5000 samples) does not contain 0.

*Table S4: Exploratory Node-Level Analysis*

|  |  |  |
| --- | --- | --- |
|   |   | **Default Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | -0.003 | -0.232 | -0.0509 | 0.0417 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.010 | 0.651 | -0.0337 | 0.0609 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.016 | 1.079 | -0.0270 | 0.0771 |
|   |   | **Dorsal Attention Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | -0.031 | -2.108 | -0.0837 | 0.0182 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.008 | 0.559 | -0.0358 | 0.0614 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.035 | 2.414 | -0.0168 | 0.1225 |
|   |   | **Fronto-Parietal Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.019 | 1.313 | -0.0307 | 0.0637 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.004 | -0.307 | -0.0475 | 0.0392 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.010 | 0.709 | -0.0316 | 0.0695 |
|   |   | **Salience Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.001 | 0.068 | -0.0531 | 0.0464 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.014 | 0.942 | -0.0237 | 0.0720 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.018 | 1.257 | -0.0316 | 0.0695 |
|   |   | **Ventral Attention Network** |
|   |   | **β** | ***t*.** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.020 | 1.355 | -0.0340 | 0.0715 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.006 | -0.401 | -0.0405 | 0.0394 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | -0.005 | -0.366 | -0.0372 | 0.0471 |
|   |   | **Cingulo-Opercular Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.016 | 1.107 | -0.0395 | 0.0685 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.008 | -0.526 | -0.0411 | 0.0425 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.014 | 0.949 | -0.0327 | 0.1260 |
|   |   | **Cingulo-Parietal Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | -0.031 | -2.112 | -0.0865 | 0.0224 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.003 | -0.215 | -0.0470 | 0.0453 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.007 | 0.491 | -0.0306 | 0.0862 |
|   |   | **Visual Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | -0.015 | 1.062 | -0.0680 | 0.0338 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.000 | 0.026 | -0.0470 | 0.0523 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.054 | 3.708 | -0.0090 | 0.1249 |
|   |   | **Auditory Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.034 | 2.353 | -0.0149 | 0.0855 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.013 | 0.869 | -0.0395 | 0.0811 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.020 | 1.404 | -0.0203 | 0.1206 |
|   |   | **Retrosplenial-Temporal Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.010 | 0.691 | -0.0401 | 0.0569 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.003 | -0.193 | -0.0459 | 0.0532 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.006 | 0.418 | -0.0363 | 0.0685 |
|   |   | **Sensorimotorhand Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.002 | 0.170 | -0.0462 | 0.0525 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | -0.003 | -0.230 | -0.0474 | 0.0512 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | -0.007 | -0.482 | -0.0402 | 0.0418 |
|   |   | **Sensorimotormouth Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | -0.017 | -1.156 | -0.0892 | 0.0438 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.024 | 1.657 | -0.0370 | 0.0994 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.044 | 3.029 | -0.0133 | 0.1828 |
|   |   | **“Other” Network** |
|   |   | **β** | ***t*** | **CI****Lower** | **CI****Upper** |
| **Degree** |  |  |  |  |  |
|  | CD Symptomatology | 0.004 | 0.251 | -0.0557 | 0.0588 |
| ***BC*** |  |  |  |  |  |
|  | CD Symptomatology | 0.009 | 0.644 | -0.0369 | 0.0693 |
| **Efficiencylocal** |  |  |  |  |  |
|  | CD Symptomatology | 0.018 | 1.206 | -0.0369 | 0.0693 |

CIs were 99.87% Bootstrapped CIs (5000 samples) to achieve the equivalent of Bonferroni correction for *p*-values when controlling for the 39 exploratory comparisons (1-[.05/39] = 0.9987).

**Supplemental Figure**

****

**Figure S1. Distribution of CD symptomatology in the current sample.** Figure S1 displays a histogram of the number of CD symptoms present in the current sample (as assessed as by K-SADS-PL).

1. 381 participants were missing data for ODD symptomatology and were excluded from any analyses using ODD symptomatology as a variable of interest. [↑](#footnote-ref-2)
2. 454 participants were missing data for ADHD symptomatology and were excluded from any analyses using ADHD symptomatology as a variable of interest. [↑](#footnote-ref-3)
3. 482 participants were missing data for SES were excluded from any analyses using SES as a variable of interest. [↑](#footnote-ref-4)